Your Cheat Sheet For Q1 Biotech Earnings

Previewing first-quarter results of biotech companies, Jefferies said it sees some modest misses across the board, going by its deduction that the first quarter tends to be soft and its Rx analysis. However, the firm said this perspective would not dampen its enthusiasm, given a recent string of positive data points/product approvals.

Signs Of Encouragement Seen

Analyst Brian Abrahams sees continued signs of encouragement for the sector as 2017 progresses, based on a few premises. Given the leadership groundwork set for an FDA that is workable and industry-friendly, the analyst believes any drastic healthcare reform measures in 2017 will be delayed, if not altogether off the table near term.

Positive Investor Sentiment

Additionally, Jeffries gets winds of the biotech stock performance building on its early momentum, based on its recent investor survey. The firm noted the 10 percent, plus, gains of the iShares NASDAQ Biotechnology Index (ETF) IBB. The firm expects the positivity to be propelled by increasing M&A activity. However, the firm cautioned of long-term competitive/pricing pressures.

Q1 Statistics

Highlighting key first-quarter statistics, the firm noted that the quarter had 62 selling days versus 63 days in fourth quarter of 2016. The quarter saw modest dollar strength. Among the potential beats are Gilead Sciences, Inc. GILD's Odefsey, Descovy and Epclusa, while Gilead Sciences' Truvada, Atripala and Complera Biogen Inc BIIB's Plegridy are among the potential misses.

Peek Into Individual Biotech Stocks (Earnings Date/Rating/Price Target

Related Links:

13 Emerging Biotechs With Catalysts In 2017

Oppenheimer Bullish On Entire Biotech Sector

Icahn's (Potential) Move Into Biotech

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorBiotechEarningsLong IdeasNewsGuidanceHealth CarePreviewsAnalyst RatingsMoversTrading IdeasGeneralAtripalaBrian AbrahamsCompleraDescovyEpclusaJefferiesOdefseyPlegridyTruvada
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!